Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Astounding Treehouses All over the Planet - 2EU Council president: Ukraine should receive binding guarantees
- 3How to watch 2026 Golden Globe winners like 'One Battle After Another,' 'Adolescence' and 'The Pitt'
- 4Staggering Spots to Stargaze All over the Planet
- 5Find the Abilities Required for Advanced Advertising Position
- 6 Pet Sitting Administrations for Your Cherished Pets
- Ukraine: Russians abduct 50 Ukrainians from border village in Sumy
- Figure out How to Advance Space in Your Pre-assembled Home for Upgraded Usefulness
- Kiefer Sutherland arrested after allegedly assaulting a ride-share driver in L.A.
- 19 Strange Motion pictures You Shouldn't Watch With Your Mum
- Historical mysteries solved by science in 2025
- Why do people have baby teeth and adult teeth?
- Exploring the Main Year of Life as a parent: Individual Encounters
- A mom's viral post is raising the question: Do kids need snacks? Dietitians have answers.
